What do systematic reviews say?

Summary of findings table ‐ Exercise plus usual pharmacological care vs another intervention (education, joint aids, or relaxation) plus usual pharmacological care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 17 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

The review found no eligible studies for this question.

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Exercise plus usual pharmacological care vs placebo + standard care

It is very uncertain whether summary of findings table ‐ Exercise plus usual pharmacological care changes withdrawals due to any reason compared with placebo plus usual pharmacological care (very low certainty).

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  RR 2.73 [0.34, 22.16]
  1 study · 21 participants
  Very low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 104 participants
  Low

Summary of findings table ‐ Exercise plus usual pharmacological care vs usual pharmacological care alone

• Exercise as adjunctive therapy for systemic lupus erythematosus 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 96 participants
  Low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all cardiovascular events compared with supragingival scaling (plus placebo) (very low certainty).

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes

  12 months
  Peto OR 7.77 [1.07, 56.1]
  1 study · 165 participants
  Very low

Periodontal treatment: scaling and root planing (SRP) plus advice vs Community care: advice only

The review found no eligible studies for this question.

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
  SoF row 'All CVD-related death': Outcome not reported. Results 2.1.2: Not reported.
  0 studies
  No studies found

Periodontal treatment: scaling and root planing (SRP) plus advice vs Community care: advice only

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes

  6 to 25 months
  All cardiovascular events (Follow-up: 6 to 25 months): One study of 303 participants assessed this outcome; however, we considered data were unreliable as participants were followed up for different lengths of time,…
  1 study · 303 participants
  Very low

Amoxicillin + metronidazole + SRP vs Supragingival scaling (plus placebo)

It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes all CVD-related death compared with supragingival scaling (plus placebo) (very low certainty).

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes

  12 months
  Peto OR 7.48 [0.15, 376.98]
  1 study · 165 participants
  Very low

Periodontal treatment: scaling and root planing (SRP) plus advice vs Community care: advice only

The review found no eligible studies for this question.

• Periodontal therapy for primary or secondary prevention of cardiovascular disease in people with periodontitis 2022 · Cochrane All outcomes
  SoF row 'All-cause death': Outcome not reported. Results 2.1.1: Not reported.
  0 studies
  No studies found

Antiplatelet drug vs control

Antiplatelet drug probably leads to lower death or dependence at end of compared with control (moderate certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.95 [0.91, 0.99]
  7 studies · 42034 participants
  Moderate

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes death from any cause during compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.93 [0.87, 0.98]
  10 studies · 41929 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes pulmonary embolism during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.71 [0.53, 0.96]
  7 studies · 41042 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes recurrent ischaemic/unknown stroke during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 0.79 [0.7, 0.88]
  9 studies · 41652 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes symptomatic intracranial haemorrhage during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 1.18 [0.97, 1.44]
  9 studies · 41652 participants
  Very low

Antiplatelet drug vs control

It is very uncertain whether antiplatelet drug changes major extracranial haemorrhage during treatment period compared with control (very low certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 1.69 [1.35, 2.11]
  7 studies · 41042 participants
  Very low

Antiplatelet drug vs control

Antiplatelet drug probably leads to higher complete recovery from stroke (post hoc) compared with control (moderate certainty).

• Oral antiplatelet therapy for acute ischaemic stroke 2022 · Cochrane Headline outcomes only
  Peto OR 1.06 [1.01, 1.11]
  2 studies · 40541 participants
  Moderate